Truvada reduces the risk of getting HIV from sex by about 99% when taken as prescribed. That makes it one of the most effective preventive medications available for any infectious disease. Its effectiveness varies depending on how it’s used (prevention vs. treatment, sex vs. injection drug use) and, critically, on how consistently you take it.
Prevention Through Daily Use (PrEP)
Truvada’s primary claim to fame is as pre-exposure prophylaxis, or PrEP. For people who don’t have HIV but are at risk of getting it, taking one pill daily brings the risk of sexual transmission down by roughly 99%. That number comes from real-world data when people take the medication consistently. The pill contains two active compounds that work together to block HIV from copying itself inside your cells. If the virus enters your body, it essentially hits a dead end and can’t establish an infection.
For people who inject drugs, the protection is lower but still meaningful. A large clinical trial in Bangkok found a 49% overall reduction in HIV infections among participants taking Truvada. Among those who actually had detectable drug levels in their blood (meaning they were genuinely taking the pills), efficacy jumped above 70%. The gap between those two numbers tells an important story: the pill only works if you take it.
How Adherence Changes the Numbers
Truvada’s effectiveness drops sharply with missed doses. Modeling based on clinical trial data shows the relationship clearly: four doses per week provides roughly 98% protection, three doses per week drops to about 96%, and two doses per week offers around 89% protection. These numbers come from studies in men who have sex with men, so they may not translate directly to other groups, but the pattern is universal. More doses means more protection, and the curve is steep at the lower end.
This is why the 99% figure and the real-world results sometimes look different. In clinical trials, not everyone takes their medication perfectly. When researchers separate participants by actual drug levels in their blood rather than just whether pills were prescribed, the protection numbers climb dramatically. If you take Truvada daily as directed, the protection is about as close to complete as a medication can get for sexual transmission.
How Long Before You’re Protected
Truvada doesn’t work instantly. The medication needs time to build up in different tissues, and the timeline varies by the type of exposure. For receptive anal sex, the pills reach maximum protection after about 7 days of daily use. For receptive vaginal sex and for injection drug use, that window extends to about 21 days.
This difference matters for anyone starting PrEP. During the ramp-up period, the medication is building toward full effectiveness but hasn’t reached it yet. Other protective measures are important during those first one to three weeks.
After a Possible Exposure (PEP)
Truvada is also used as part of post-exposure prophylaxis, taken after a potential HIV exposure rather than before. PEP must be started within 72 hours of exposure and continued daily for 28 days. The NIH estimates that PEP reduces the risk of HIV infection by more than 80%, and the true effectiveness is likely considerably higher when you complete the full course without missing doses and avoid additional exposures during treatment.
The 80% figure is a conservative estimate because PEP is difficult to study in controlled trials. You can’t ethically expose people to HIV and then randomly assign some to receive treatment and others a placebo. So the data comes from observational studies, which tend to undercount effectiveness. Consistent use of the full 28-day course almost certainly provides stronger protection than that baseline number suggests.
As Part of HIV Treatment
Beyond prevention, Truvada serves as a backbone of combination therapy for people already living with HIV. It’s not used alone for treatment but paired with a third medication. Modern regimens that include Truvada’s components achieve viral suppression (meaning the virus becomes undetectable in the blood) in about 95% of patients at six months and 96% at twelve months. By two years, that figure reaches 98%.
Reaching an undetectable viral load is significant for two reasons. It keeps the immune system healthy, and it eliminates the risk of transmitting HIV to sexual partners. This concept, sometimes called “undetectable equals untransmittable,” has been confirmed in large studies of couples where one partner is HIV-positive and on effective treatment.
Newer Alternatives to Truvada
Truvada was the first medication approved for PrEP, but it’s no longer the only option. A newer daily pill called Descovy uses a different form of one of the same active ingredients and is associated with fewer kidney and bone concerns. An injectable option given every two months is also available, and in 2025 the CDC updated its PrEP guidelines to include a twice-yearly injection as another choice. These alternatives exist partly to give options to people who struggle with daily pills, since adherence is the single biggest factor in how well any PrEP regimen works.
Kidney and Bone Health Considerations
Truvada’s two components can affect kidney function and bone density over time. These effects are typically mild and reversible after stopping the medication, but they’re worth understanding. In one large study of people prescribed oral PrEP, about 7.4% showed mildly reduced kidney function on lab testing. Many PrEP users also have other factors that independently affect kidney or bone health, including other medications, existing health conditions, or simply age, which can make it harder to isolate Truvada’s contribution.
Routine monitoring is part of standard PrEP care. Kidney function is checked before starting and periodically while on the medication. For most healthy adults, these side effects remain in the “measurable but not clinically significant” category. The more common day-to-day side effects, like nausea or headache, tend to appear in the first few weeks and then fade. Serious complications are rare.
The Bottom Line on Effectiveness
Truvada’s effectiveness ranges from very good to near-perfect depending on the use case and adherence. At 99% risk reduction for sexual transmission with daily use, it outperforms most preventive interventions in medicine. For injection drug use, the protection is lower (49% to 70%+), reflecting both the biology of that transmission route and the challenges of consistent daily dosing in that population. As post-exposure treatment, it likely exceeds 80% effectiveness. And as part of HIV treatment, it helps achieve viral suppression in the high 90s percentage-wise. In every scenario, the common thread is the same: the closer you stick to the prescribed regimen, the better it works.